This study assesses the effectiveness of both preoperative chemoradiation with cisplatin and fluorouracil or carboplatin and paclitaxel on recurrence-free survival and overall survival in patients with esophageal cancer.
This study uses disease registry data to examine the association between time intervals from the completion of neoadjuvant chemoradiotherapy to surgical procedure and rates of pathologic complete responses in patients with esophageal cancer.
This study reports that patients with node-positive esophageal adenocarcinoma benefit significantly from neoadjuvant chemoradiation, while patients with node-negative tumors do not gain significant overall survival as compared with surgery alone.
This cohort study reports that the extent of lymphadenectomy during surgery for esophageal cancer is not associated with 5-year all-cause or disease-specific survival.
This retrospective medical record review examines the role of positron emission tomography–computed tomography characteristics in esophageal adenocarcinoma for patients undergoing neoadjuvant chemoradiotherapy and demonstrates that a δ standardized uptake variable value of less than 45% reliably predicts patients who have residual disease but not complete pathologic response.